Hepatocellular carcinoma, a type of liver cancer, is the sixth most common cancer worldwide and the third leading cause of ...

Immune checkpoint inhibitor tumor regression may indicate which patients with hepatocellular carcinoma experience improved ...

A new risk score model for hepatocellular carcinoma using standard clinical data can better identify individuals at risk ...

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study ...

University of Iowa researchers have been awarded federal funding to help develop an effective drug combination to treat a ...

Researchers at the University of Iowa are part of a project designed to enhance treatment options for a common form of liver ...

Symptoms can include upper abdominal pain, yellow discolouration of the skin and general widespread weakness in the body.

Hepatocellular carcinoma (HCC) is a significant global health concern, particularly in regions like the Asia-Pacific, where chronic viral hepatitis and liver diseases contribute to its high incidence ...

It offers a non-invasive approach and has broad clinical relevance in cancer management. This comprehensive review primarily ...

Liver cancer is the sixth leading cause of cancer death in the U.S. The most common type of liver cancer in adults is ...

Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...